a7051b
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of October 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
COVID-19 antibodies
advance and get US funding
9 October 2020 21:30 BST
COVID-19 Long-Acting AntiBody (LAAB) combination
AZD7442
rapidly advances into Phase III clinical trials
Two trials of AZD7442 will enrol over 6,000 adults for the
prevention of COVID-19 with additional trials
enrolling ~4,000
adults for the treatment of SARS-CoV-2
infections
US Government to invest ~$486m for development and
supply
of up to 100,000 doses and can acquire another one million
doses
AstraZeneca's long-acting antibody (LAAB) combination, AZD7442,
will advance into two Phase III clinical trials in more than 6,000
participants at sites in and outside the US that are due to begin
in the next weeks. The LAABs have been engineered with
AstraZeneca's proprietary half-life extension technology to
increase the durability of the therapy for six to 12 months
following a single administration. The combination of two LAABs is
also designed to reduce the risk of resistance developed by the
SARS-CoV-2 virus.
The Company has received support of around $486m from the US
Government for the development and supply of AZD7442 under an
agreement with the Biomedical Advanced Research and Development
Authority (BARDA), part of the Office of the Assistant Secretary
for Preparedness and Response at the US Department of Health and
Human Services, and the Department of Defense Joint Program
Executive Office for Chemical, Biological, Radiological and Nuclear
Defense.
One trial will evaluate the safety and efficacy of AZD7442 to
prevent infection for up to 12 months, in approximately 5,000
participants. The second trial will evaluate post-exposure
prophylaxis and pre-emptive treatment in approximately 1,100
participants.
AstraZeneca is planning additional trials to evaluate AZD7442 in
approximately 4,000 patients for the treatment of
COVID-19.
AstraZeneca plans to supply up to 100,000 doses starting towards
the end of 2020 and the US Government can acquire up to an
additional one million doses in 2021 under a separate
agreement.
Pascal Soriot, Chief Executive Officer, said: "This agreement with
the US Government will help accelerate the development of our
long-acting antibody combination which has the potential to provide
immediate and long-lasting effect in both preventing and treating
COVID-19 infections. We will be evaluating the LAAB combination in
different settings from prophylaxis, to outpatient treatment to
hospitalisation, with a focus on helping the most vulnerable
people."
LAABs mimic natural antibodies and have the potential to treat and
prevent disease progression in patients already infected with the
virus, as well as to be given as a preventative intervention prior
to exposure to the virus. A LAAB combination could be complementary
to vaccines as a prophylactic agent, e.g. for people for whom a
vaccine may not be appropriate or to provide added protection for
high-risk populations. It could also be used to treat people who
have been infected.
Today's agreement builds on previous funding of more than $25m from
US government agencies BARDA and the Defense Advanced Research
Projects Agency for the discovery and evaluation of the monoclonal
antibodies, as well as the Phase I clinical trial started in August
20201 to
assess safety, tolerability and pharmacokinetics of AZD7442 in
healthy individuals.
Financial considerations
The agreement is not anticipated to impact the Company's financial
guidance for 2020 as the US Government funding is being offset by
expenses to progress the clinical trials of AZD7442 as well as
manufacturing process and upscaling costs. Should the Phase III
trials prove successful and AZD7442 become an approved medicine,
the Company anticipates providing the medicine at commercial terms
during and after the current coronavirus pandemic.
AZD7442
AZD7442 is a combination of two LAABs derived from
convalescent patients after SARS-CoV-2 infection. Discovered by
Vanderbilt University Medical Center and licensed to
AstraZeneca in June 2020,
the LAABs were optimised by AstraZeneca with half-life
extension and reduced Fc receptor binding. The half-life
extended LAABs should afford six to 12 months of
protection from COVID-19.2-5 The
reduced Fc receptor binding aims to minimise the risk of
antibody-dependent enhancement of disease - a phenomenon in which
virus-specific antibodies promote, rather than inhibit, infection
and/or disease.6
In a recent Nature publication,
the LAABs were shown in pre-clinical experiments to block
the binding of the SARS-CoV-2 virus to host cells and protect
against infection in cell and animal models of
disease.7
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
ClinicalTrials.gov.
NCT04507256. https://clinicaltrials.gov/ct2/show/NCT04507256?term=NCT04507256&draw=2&rank=1.
2.
Robbie, G.J., et al., A novel investigational
Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an
extended half-life in healthy adults. Antimicrob Agents
Chemother, 2013. 57(12): p.
6147-53.
3.
Griffin, M.P., et al., Safety, Tolerability, and
Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus
Prefusion F-Targeting Monoclonal Antibody with an Extended
Half-Life, in Healthy Adults. Antimicrob Agents
Chemother, 2017.
61(3).
4.
Yu, X.Q., et al., Safety, Tolerability, and
Pharmacokinetics of MEDI4893, an Investigational,
Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human
Monoclonal Antibody, in Healthy Adults. Antimicrob Agents
Chemother, 2017.
61(1).
5.
Domachowske, J.B., et al., Safety, Tolerability
and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose
Respiratory Syncytial Virus Prefusion F-targeting Monoclonal
Antibody Administered as a Single Dose to Healthy Preterm
Infants. Pediatr Infect Dis
J, 2018. 37(9): p.
886-892.
6.
Van Erp EA, Luytjes W, Ferwerda G and van Kasteren
PB. Fc-Mediated Antibody Effector Functions During Respiratory
Syncytial Virus Infection and Disease. Front.
Immunol. 2019.
https://doi.org/10.3389/fimmu.2019.00548.
7.
Zost SJ et al. Potently neutralizing human
antibodies that block SARS-CoV-2 receptor binding and protect
animals. Nature. 2020. DOI:
10.1038/s41586-020-2548-6.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
12 October
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|